Tribenzor (Olmesartan/Amlodipin/HCThiazid) Patent Expiration, LOE Window & CMS Spending

Tribenzor (Olmesartan/Amlodipin/HCThiazid) by Cosette Pharmac: Off-Patent Genericized (AB Competition), 0 AB generics, $1.6M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorCosette Pharmac
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.6M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$69K
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 32.9% 2-yr change)